APRI (Aprinoia Therapeutics) Other Current Receivables: $0.00 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Other Current Receivables?

Aprinoia Therapeutics APRI Other Current Receivables is $0.00 Mil as of Dec. 2023.

Aprinoia Therapeutics's Other Current Receivables for the quarter that ended in Dec. 2023 was $0.00 Mil.

Aprinoia Therapeutics Other Current Receivables Related Terms

Aprinoia Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Other Current Receivables Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Other Current Receivables
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Receivables 0.00 0.00 0.00 0.00 0.00

Aprinoia Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.00 Mil mean?
Aprinoia Therapeutics (APRI) has a Other Current Receivables of $0.00 Mil as of Dec. 2023. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Other Current Receivables too high?
Aprinoia Therapeutics' current Other Current Receivables is $0.00 Mil.
How does Aprinoia Therapeutics' Other Current Receivables compare to ?
Aprinoia Therapeutics' Other Current Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Other Current Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Other Current Receivables of $0.00 Mil. The current Other Current Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Other Current Receivables is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.